- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
1 report, 1 independent
Updated May 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- New FDA rule threatens the ability to import medicines.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- The Dietary Supplement Health and Education Act established the regulatory framework, with FDA oversight affecting the supplement industry.
- Both the FDA and European Medicines Agency must adopt evidence-based principles for drug regulation.
- Research advances have led to the approval of new therapies by the FDA.